- Home
- GLTO
GLTO
Galecto Inc.
as 01-22-2025 4:00pm EST
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
| Founded: | 2011 | Country: | Denmark |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 6.5M | IPO Year: | 2020 |
| Target Price: | $10.00 | AVG Volume (30 days): | 21.2K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -19.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.40 - $23.50 | Next Earning Date: | 03-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Galecto Inc. (GLTO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Winslow Garrett | GLTO | General Counsel | Jan 3 '25 | Sell | $5.60 | 471 | $2,637.60 | 1,009 | |
| Schambye Hans T. | GLTO | Chief Executive Officer | Jan 3 '25 | Sell | $5.60 | 1,341 | $7,509.60 | 3,397 | |
| Firmani Lori | GLTO | Interim CFO | Jan 3 '25 | Sell | $5.63 | 261 | $1,469.43 | 465 |
Latest Galecto Inc. News
GLTO Breaking Stock News: Dive into GLTO Ticker-Specific Updates for Smart Investing
Zacks
2 months ago
Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
GlobeNewswire
3 months ago
Galecto Reports Third Quarter 2024 Financial Results
TipRanks
3 months ago
Galecto price target raised to $10 from $9 at Oppenheimer
GlobeNewswire
3 months ago
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler
MT Newswires
4 months ago
Galecto to Focus on Cancer, Liver Disease After Strategic Review; Shares Fall
GlobeNewswire
4 months ago
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
MT Newswires
4 months ago
Galecto Regains Compliance With Nasdaq Minimum Bid Price Rule
MT Newswires
5 months ago
Galecto to Implement 1-for-25 Reverse Stock Split
Compare GLTO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GLTO Galecto Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.